SynAct Pharma AB (OSTO:SYNACT) Issuance of Debt: kr0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SYNACT SynAct Pharma AB OSTO:SYNACT
27 GF Score
Price kr19.10
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB Issuance of Debt?

SynAct Pharma AB OSTO:SYNACT +5.76% 27 Issuance of Debt is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:SYNACT with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

SynAct Pharma AB's Issuance of Debt for the three months ended in Mar. 2026 was kr0.00 Mil.

SynAct Pharma AB's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

SynAct Pharma AB Issuance of Debt Related Terms

SynAct Pharma AB Issuance of Debt Historical Data

* Premium members only.

The historical data trend for SynAct Pharma AB's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynAct Pharma AB Issuance of Debt Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SynAct Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:SYNACT
27GF Score
SynAct Pharma AB OSTO:SYNACT
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of kr0.00 Mil mean?
SynAct Pharma AB (OSTO:SYNACT) has a Issuance of Debt of kr0.00 Mil as of Mar. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on SynAct Pharma AB and its competitors.
Is SynAct Pharma AB's Issuance of Debt too high?
SynAct Pharma AB's current Issuance of Debt is kr0.00 Mil. Overall, SynAct Pharma AB has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's Issuance of Debt compare to VRTX and REGN?
SynAct Pharma AB's Issuance of Debt of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on SynAct Pharma AB and its competitors. SynAct Pharma AB's current Issuance of Debt is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (OSTO:SYNACT) has a current Issuance of Debt of kr0.00 Mil. The current Issuance of Debt is kr0.00 Mil. SynAct Pharma AB's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For SynAct Pharma AB (OSTO:SYNACT), the current Issuance of Debt is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SynAct Pharma AB Business Description

Other Exchanges 8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
27GF Score

Get the complete analysis for OSTO:SYNACT

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr19.10
Price